Diabetes

News

The pricing agreement between Novo Nordisk and Eli Lilly and the Trump administration on GLP-1 drugs for diabetes and obesity has arrived.

News

Innovent's dual glucagon and GLP-1 agonist mazdutide outperforms Novo Nordisk's Ozempic in overweight people with diabetes.

News

Eli Lilly has built the case for its oral GLP-1 orforglipron with two more phase 3 readouts, including a head-to-head win over Farxiga in diabetes.

News

Eli Lilly is preparing to file for approval of its oral weight-loss drug orforglipron before year-end, but not all are convinced by the data.

News

Novo Nordisk's Rybelsus has become the first oral GLP-1 agonist to pick up a regulatory approval for cardiovascular risk reduction.

News

Replicate will receive up to $550m from Novo Nordisk in an alliance that aims to deliver a new generation of drugs for obesity and diabetes.